PT - JOURNAL ARTICLE AU - Oelsner, Elizabeth C AU - Allen, Norrina Bai AU - Ali, Tauqeer AU - Anugu, Pramod AU - Andrews, Howard AU - Asaro, Alyssa AU - Balte, Pallavi P AU - Barr, R Graham AU - Bertoni, Alain G AU - Bon, Jessica AU - Boyle, Rebekah AU - Chang, Arunee A AU - Chen, Grace AU - Cole, Shelley A AU - Coresh, Josef AU - Cornell, Elaine AU - Correa, Adolfo AU - Couper, David AU - Cushman, Mary AU - Demmer, Ryan T AU - Elkind, Mitchell S. V. AU - Folsom, Aaron R AU - Fretts, Amanda M AU - Gabriel, Kelley Pettee AU - Gallo, Linda AU - Gutierrez, Jose AU - Han, MeiLan K. AU - Henderson, Joel M AU - Howard, Virginia J AU - Isasi, Carmen R AU - Jacobs, David R AU - Judd, Suzanne E AU - Mukaz, Debora Kamin AU - Kanaya, Alka M AU - Kandula, Namratha R AU - Kaplan, Robert AU - Krishnaswamy, Akshaya AU - Kinney, Gregory L AU - Kucharska-Newton, Anna AU - Lee, Joyce S. AU - Lewis, Cora E AU - Levine, Deborah A. AU - Levitan, Emily B. AU - Levy, Bruce AU - Make, Barry AU - Malloy, Kimberly AU - Manly, Jennifer J AU - Meyer, Katie A AU - Min, Yuan-I AU - Moll, Matthew AU - Moore, Wendy C. AU - Mauger, Dave AU - Ortega, Victor E. AU - Palta, Priya AU - Parker, Monica M AU - Phipatanakul, Wanda AU - Post, Wendy AU - Psaty, Bruce M AU - Regan, Elizabeth A AU - Ring, Kimberly AU - Roger, Véronique L. AU - Rotter, Jerome I AU - Rundek, Tatjana AU - Sacco, Ralph L. AU - Schembri, Michael AU - Schwartz, David A. AU - Seshadri, Sudha AU - Shikany, James M AU - Sims, Mario AU - Hinckley Stukovsky, Karen D AU - Talavera, Gregory A AU - Tracy, Russell P AU - Umans, Jason G AU - Vasan, Ramachandran S AU - Watson, Karol AU - Wenzel, Sally E. AU - Winters, Karen AU - Woodruff, Prescott G. AU - Xanthakis, Vanessa AU - Zhang, Ying AU - Zhang, Yiyi AU - , TI - Collaborative Cohort of Cohorts for COVID-19 Research (C4R) Study: Study Design AID - 10.1101/2021.03.19.21253986 DP - 2021 Jan 01 TA - medRxiv PG - 2021.03.19.21253986 4099 - http://medrxiv.org/content/early/2021/03/20/2021.03.19.21253986.short 4100 - http://medrxiv.org/content/early/2021/03/20/2021.03.19.21253986.full AB - The Collaborative Cohort of Cohorts for COVID-19 Research (C4R) is a national prospective study of adults at risk for coronavirus disease 2019 (COVID-19) comprising 14 established United States (US) prospective cohort studies. For decades, C4R cohorts have collected extensive data on clinical and subclinical diseases and their risk factors, including behavior, cognition, biomarkers, and social determinants of health. C4R will link this pre-COVID phenotyping to information on SARS-CoV-2 infection and acute and post-acute COVID-related illness. C4R is largely population-based, has an age range of 18-108 years, and broadly reflects the racial, ethnic, socioeconomic, and geographic diversity of the US. C4R is ascertaining severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and COVID-19 illness using standardized questionnaires, ascertainment of COVID-related hospitalizations and deaths, and a SARS-CoV-2 serosurvey via dried blood spots. Master protocols leverage existing robust retention rates for telephone and in-person examinations, and high-quality events surveillance. Extensive pre-pandemic data minimize referral, survival, and recall bias. Data are being harmonized with research-quality phenotyping unmatched by clinical and survey-based studies; these will be pooled and shared widely to expedite collaboration and scientific findings. This unique resource will allow evaluation of risk and resilience factors for COVID-19 severity and outcomes, including post-acute sequelae, and assessment of the social and behavioral impact of the pandemic on long-term trajectories of health and aging.Competing Interest StatementMitchell Elkind receives royalties from UpToDate for a chapter on neurological complications of COVID-19; receives study drug in kind from the BMS-Pfizer Alliance for Eliquis and ancillary funding from Roche, both for an NIH-funded trial of stroke prevention. MeiLan K Han reports consulting for BI, GSK, AZ, Merck, Mylan, Verona, Teva, Cipla, Chiesi and Sanofi. She reports research support from Novartis and Sunovion. Emily B. Levitan has research funding from Amgen and has received consulting fees for a research project sponsored by Novartis. Wanda Phipatanakul has funding and trial medication support from Astra Zeneca, GSK, Merck, Genentech, Novartis, Regeneron, Sanofi for asthma studies and consulting from GSK, Genentech, Novartis, Sanofi, Regeneron for asthma therapeutics. Bruce M Psaty serves on the Steering Committee of the Yale Open Data Access Project funded by Johnson & Johnson. David Schwartz is founder and chief scientific officer of Eleven P15, a company dedicated to the diagnosis, prevention, and treatment of early presentations of pulmonary fibrosis. Joyce Lee serves as a consultant for Eleven P15. Sally Wenzel receives funding for consulting and clinical trials from AstraZeneca, GSK, Sanofi-Genzyme, Novartis, Knopp; she also receives research support from Pieris and Regeneron. Prescott Woodruff has a research grant from Genentech and is a consultant for Sanofi, Regeneron, Clarus ventures, 23andMe, Theravance, Astra Zeneca, Glenmark Pharmaceuticals, Amgen, and NGM Pharma, outside the submitted work.Clinical Protocols https://c4r-nih.org/ Funding StatementC4R: C4R is supported by NHLBI-CONNECTS OT2HL156812 ARIC: The Atherosclerosis Risk in Communities study has been funded in whole or in part with Federal funds from the National Heart, Lung, and Blood Institute, National Institutes of Health, Department of Health and Human Services, under Contract nos. (HHSN268201700001I, HHSN268201700002I, HHSN268201700003I, HHSN268201700005I, HHSN268201700004I). Neurocognitive data are collected by U01 2U01HL096812, 2U01HL096814, 2U01HL096899, 2U01HL096902, 2U01HL096917 from the NHLBI, NINDS, NIA and NIDCD. Ancillary studies funded additional data elements. BP COGThe BP COG Study is supported by the National Institute of Neurological Disorders and Stroke, National Institutes of Health, and US Department of Health and Human Services (grant R01 NS102715). CARDIA: The Coronary Artery Risk Development in Young Adults Study (CARDIA) is conducted and supported by the National Heart, Lung, and Blood Institute (NHLBI) in collaboration with the University of Alabama at Birmingham (HHSN268201800005I, HHSN268201800007I), Northwestern University (HHSN268201800003I), University of Minnesota (HHSN268201800006I), and Kaiser Foundation Research Institute (HHSN268201800004I). This manuscript has been reviewed by CARDIA for scientific content. COPDGene: The project described was supported by Award Number U01 HL089897 and Award Number U01 HL089856 from the National Heart, Lung, and Blood Institute. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Heart, Lung, and Blood Institute or the National Institutes of Health. COPD Foundation Funding: COPDGene is also supported by the COPD Foundation through contributions made to an Industry Advisory Board comprised of AstraZeneca, Boehringer-Ingelheim, Genentech, GlaxoSmithKline, Novartis, Pfizer, Siemens, and Sunovion. FHS: The Framingham Heart Study (FHS) acknowledges the support of Contracts NO1-HC-25195, HHSN268201500001I and 75N92019D00031 from the National Heart, Lung and Blood Institute. We also acknowledge the dedication of the FHS study participants without whom this research would not be possible. HCHS/SOL: The Hispanic Community Health Study/Study of Latinos is a collaborative study supported by contracts from the National Heart, Lung, and Blood Institute (NHLBI) to the University of North Carolina (HHSN268201300001I, N01-HC-65233), University of Miami (HHSN268201300004I, N01-HC-65234), Albert Einstein College of Medicine (HHSN268201300002I, N01-HC-65235), University of Illinois at Chicago, HHSN268201300003I, N01-HC-65236 Northwestern Univ), and San Diego State University (HHSN268201300005I, N01-HC-65237). The following Institutes/Centers/Offices have contributed to the HCHS/SOL through a transfer of funds to the NHLBI: National Institute on Minority Health and Health Disparities, National Institute on Deafness and Other Communication Disorders, National Institute of Dental and Craniofacial Research, National Institute of Diabetes and Digestive and Kidney Diseases, National Institute of Neurological Disorders and Stroke, NIH Institution-Office of Dietary Supplements. JHS: The Jackson Heart Study (JHS) is supported and conducted in collaboration with Jackson State University (HHSN268201800013I), Tougaloo College (HHSN268201800014I), the Mississippi State Department of Health (HHSN268201800015I) and the University of Mississippi Medical Center (HHSN268201800010I, HHSN268201800011I and HHSN268201800012I) contracts from the National Heart, Lung, and Blood Institute (NHLBI) and the National Institute on Minority Health and Health Disparities (NIMHD). MASALA: MASALA was supported by Grant Number R01HL093009 from the National Heart, Lung, And Blood Institute and the National Center for Research Resources and the National Center for Advancing Translational Sciences, National Institutes of Health, through UCSF-CTSI Grant Number UL1RR024131. MESA: MESA and the MESA SHARe projects are conducted and supported by the National Heart, Lung, and Blood Institute (NHLBI) in collaboration with MESA investigators. Support for MESA is provided by contracts and grants 75N92020D00001, HHSN268201500003I, N01-HC-95159, 75N92020D00005, N01-HC-95160, 75N92020D00002, N01-HC-95161, 75N92020D00003, N01-HC-95162, 75N92020D00006, N01-HC-95163, 75N92020D00004, N01-HC-95164, 75N92020D00007, N01-HC-95165, N01-HC-95166, N01-HC-95167, N01-HC-95168, N01-HC-95169, R01-HL077612, R01-HL093081, R01-HL130506, R01-HL127028, R01-HL127659, R01-HL098433, R01-HL101250, and R01-HL135009 from the National Heart, Lung, and Blood Institute; R01-AG058969 from the National Institute on Aging; and by grants UL1-TR-000040, UL1-TR-001079, and UL1-TR-001420 from the National Center for Advancing Translational Sciences (NCATS). Funding for SHARe genotyping was provided by NHLBI Contract N02-HL-64278. This publication was developed under the Science to Achieve Results (STAR) research assistance agreements, No. RD831697 (MESA Air) and RD-83830001 (MESA Air Next Stage), awarded by the U.S Environmental Protection Agency. It has not been formally reviewed by the EPA. The views expressed in this document are solely those of the authors and the EPA does not endorse any products or commercial services mentioned in this publication. Whole genome sequencing (WGS) for the Trans-Omics in Precision Medicine (TOPMed) program was supported by the NHLBI. WGS for NHLBI TOPMed: Multi-Ethnic Study of Atherosclerosis (MESA) (phs001416.v1.p1) was performed at the Broad Institute of MIT and Harvard (3U54HG003067-13S1). Centralized read mapping and genotype calling, along with variant quality metrics and filtering were provided by the TOPMed Informatics Research Center (3R01HL-117626-02S1, contract HHSN268201800002I) (Broad RNA Seq, Proteomics HHSN268201600034I, UW RNA Seq HHSN268201600032I, USC DNA Methylation HHSN268201600034I, Broad Metabolomics HHSN268201600038I). Phenotype harmonization, data management, sample-identity QC, and general study coordination, were provided by the TOPMed Data Coordinating Center (3R01HL-120393; U01HL-120393; contract HHSN268180001I). The provision of genotyping data was supported in part by the National Center for Advancing Translational Sciences, CTSI grant UL1TR001881, and the National Institute of Diabetes and Digestive and Kidney Disease Diabetes Research Center (DRC) grant DK063491 to the Southern California Diabetes Endocrinology Research Center. The authors thank the other investigators, the staff, and the participants of the MESA study for their valuable contributions. A full list of participating MESA investigators and institutions can be found at http://www.mesa-nhlbi.org. NHLBI Pooled Cohorts Study: NIH/NHLBI R21HL153700, K23HL130627, R21HL129924), R21HL121457 NOMAS: Supported by NINDS R01 NS29993 and R01 AG066162. PrePF: Prevent Pulmonary Fibrosis cohort was established in 2000 and has been supported by: X01-ES101947, R01-HL095393, RC2-HL1011715, R21/33-HL120770, R01-HL097163, X01-HL134585, UH2/3-HL123442, P01-HL092870, UG3/UH3-HL151865, and DoD W81XWH-17-1-0597. REGARDS: This research project is supported by cooperative agreement U01 NS041588 co-funded by the National Institute of Neurological Disorders and Stroke (NINDS) and the National Institute on Aging (NIA), National Institutes of Health, Department of Health and Human Service. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NINDS or the NIA. Representatives of the NINDS were involved in the review of the manuscript but were not directly involved in the collection, management, analysis or interpretation of the data. The authors thank the other investigators, the staff, and the participants of the REGARDS study for their valuable contributions. A full list of participating REGARDS investigators and institutions can be found at: https://www.uab.edu/soph/regardsstudy/ SARP: The research by the principal and co-principal investigators was funded by National Institutes of Health/National Heart Lung Blood Institute (NIH/NHLBI) Severe Asthma Research Program: U10 HL109164, U10 HL109257, U10 HL109146), U10 HL109172, U10 HL109250, U10 HL109168, U10 HL109152, U10 HL109086). Industry Partnerships also provided additional support: AstraZeneca, Boehringer-Ingelheim, Genetech, GlaxoSmithKline, MedImmune, Novartis, Regeneron, Sanofi and TEVA. Spirometers used in SARP III were provided by nSpire Health (Longmont, Colo). SPIROMICS: SPIROMICS has been funded by contracts from the NIH/NHLBI (HHSN268200900013C, HHSN268200900014C, HHSN268200900015C, HHSN268200900016C, HHSN268200900017C, HHSN268200900018C, HHSN268200900019C, HHSN268200900020C), grants from the NIH/NHLBI (U01 HL137880 and U24 HL141762), and supplemented by contributions made through the Foundation for the NIH and the COPD Foundation from AstraZeneca/MedImmune; Bayer; Bellerophon Therapeutics; Boehringer-Ingelheim Pharmaceuticals, Inc.; Chiesi Farmaceutici S.p.A.; Forest Research Institute, Inc.; GlaxoSmithKline; Grifols Therapeutics, Inc.; Ikaria, Inc.; Novartis Pharmaceuticals Corporation; Nycomed GmbH; ProterixBio; Regeneron Pharmaceuticals, Inc.; Sanofi; Sunovion; Takeda Pharmaceutical Company; and Theravance Biopharma and Mylan. SHS: The Strong Heart Study has been funded in whole or in part with federal funds from the National Heart, Lung, and Blood Institute, National Institute of Health, Department of Health and Human Services, under contract numbers 75N92019D00027, 75N92019D00028, 75N92019D00029, & 75N92019D00030. The study was previously supported by research grants: R01HL109315, R01HL109301, R01HL109284, R01HL109282, and R01HL109319 and by cooperative agreements: U01HL41642, U01HL41652, U01HL41654, U01HL65520, and U01HL65521.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:C4R has been approved by the Columbia University Irving Medical Center IRB as well as cohort and site-specific IRBs. The design paper was approved the Steering Committees of all participating cohorts as well as NHLBI-CONNECTS.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesFollowing review and approval, cohort-specific agreements would permit COVID-19 and pre-pandemic data from C4R to be uploaded to the NIH-supported cloud computing platform, hosted by BioData Catalyst.AbbreviationsARICAtherosclerosis Risk in CommunitiesBCLBiorepository and Central LaboratoryC4RCollaborative Cohort of Cohorts for COVID-19 ResearchCARDIACoronary Artery Risk Development in Young AdultsCONNECTSCollaborating Network of Networks for Evaluating COVID-19 and Therapeutic StrategiesCOPDGeneGenetic Epidemiology of COPDFHSFramingham Heart StudyHCHS/SOLHispanic Community Health Study/Study of LatinosJHSJackson Heart StudyMASALAMediators of Atherosclerosis in South Asians Living in AmericaMESAMulti-Ethnic Study of AtherosclerosisNOMASNorthern Manhattan StudyPASCPost-Acute Sequelae of SARS-CoV-2 InfectionPrePFPrevent Pulmonary FibrosisREGARDSREasons for Geographic and Racial Differences in StrokeSARPSevere Asthma Research ProgramSPIROMICSSubpopulations and Intermediate Outcome Measures in COPD StudySHSStrong Heart Study